| scholarly article | Q13442814 |
| P2093 | author name string | Abdulbari Bener | |
| Amin Jayyousi | |||
| Mahmoud Zirie | |||
| Bilal Zuby | |||
| Lolwa Barakat | |||
| P2860 | cites work | Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin. | Q53946077 |
| The effect of statins on urinary albumin excretion and glomerular filtration rate: results from both a randomized clinical trial and an observational cohort study | Q57316371 | ||
| Statins, High-Density Lipoprotein Cholesterol, and Regression of Coronary Atherosclerosis | Q57740244 | ||
| Hyperlipidemia and diabetes mellitus | Q77461273 | ||
| Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study | Q83862765 | ||
| Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report | Q27861020 | ||
| Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial | Q29622926 | ||
| Current perspectives on statins | Q33818381 | ||
| Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). | Q34214164 | ||
| Efficacy and safety of rosuvastatin in treatment of dyslipidemia. | Q34419733 | ||
| Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors | Q34460973 | ||
| Risks associated with statin therapy: a systematic overview of randomized clinical trials | Q34589564 | ||
| The safety of statins in clinical practice | Q34636135 | ||
| Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same? | Q34757699 | ||
| Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation | Q34765654 | ||
| The relationship of statins to rhabdomyolysis, malignancy, and hepatic toxicity: evidence from clinical trials | Q34948312 | ||
| Comparison of the efficacy and safety of rosuvastatin 10 mg and atorvastatin 20 mg in high-risk patients with hypercholesterolemia--Prospective study to evaluate the Use of Low doses of the Statins Atorvastatin and Rosuvastatin (PULSAR) | Q35605494 | ||
| Rosuvastatin: a new inhibitor of HMG-coA reductase for the treatment of dyslipidemia | Q35696163 | ||
| Lipids and lipoproteins in patients with type 2 diabetes | Q35783120 | ||
| Association between psychological distress and gastrointestinal symptoms in diabetes mellitus | Q36057076 | ||
| Safety of statins: effects on muscle and the liver. | Q36325914 | ||
| Should both HDL-C and LDL-C be targets for lipid therapy? A review of current evidence | Q36422727 | ||
| Meta-analysis: the effect of statins on albuminuria | Q36538949 | ||
| Statins and myotoxicity: a therapeutic limitation | Q36565044 | ||
| Standards of medical care in diabetes--2009. | Q37036416 | ||
| Prevalence of diagnosed and undiagnosed diabetes mellitus and its risk factors in a population-based study of Qatar | Q39876466 | ||
| Prevalence of metabolic syndrome according to Adult Treatment Panel III and International Diabetes Federation criteria: a population-based study | Q39879020 | ||
| Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing | Q44491215 | ||
| P275 | copyright license | Creative Commons Attribution 3.0 Unported | Q14947546 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P304 | page(s) | 146579 | |
| P577 | publication date | 2013-02-10 | |
| P1433 | published in | ISRN Pharmacology | Q26842344 |
| P1476 | title | Comparison of Efficacy and Safety of Rosuvastatin, Atorvastatin and Pravastatin among Dyslipidemic Diabetic Patients | |
| P478 | volume | 2013 |
| Q53567130 | 1.2% Rosuvastatin and 1.2% Atorvastatin Gel Local Drug Delivery and Redelivery in the Treatment of Class II Furcation Defects: A Randomized Controlled Clinical Trial. |
| Q37551536 | Comparison of efficacy, safety, and cost-effectiveness of various statins in dyslipidemic diabetic patients |
| Q49189576 | Comparison of lipid profiles and inflammation in pre- and post-menopausal women with cerebral infarction and the role of atorvastatin in such populations |
| Q37700760 | Comparison of low-dose rosuvastatin with atorvastatin in lipid-lowering efficacy and safety in a high-risk pakistani cohort: an open-label randomized trial |
| Q43693480 | Effects of silymarin on the pharmacokinetics of atorvastatin in diabetic rats |
| Q99239224 | Efficacy and Tolerability of a Fixed-Dose Combination of Rosuvastatin and Ezetimibe Compared with a Fixed-Dose Combination of Simvastatin and Ezetimibe in Brazilian Patients with Primary Hypercholesterolemia or Mixed Dyslipidemia: A Multicenter, Ran |
| Q50016659 | Food Effect on Rosuvastatin Disposition and Low-Density Lipoprotein Cholesterol |
| Q34486159 | Highly sensitive ligand-binding assays in pre-clinical and clinical applications: immuno-PCR and other emerging techniques. |
| Q58197587 | Immunological aspects of atherosclerosis |
| Q37036035 | Improvement of Glycemic Control in Insulin-Dependent Diabetics with Depression by Concomitant Treatment with Antidepressants |
Search more.